Cytek Biosciences Inc (NAS:CTKB)
$ 5.6 0.03 (0.54%) Market Cap: 735.13 Mil Enterprise Value: 479.43 Mil PE Ratio: 0 PB Ratio: 1.87 GF Score: 60/100

Cytek Biosciences Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 11:50PM GMT
Release Date Price: $13.7 (-5.65%)
Wenbin Jiang
Cytek Biosciences, Inc. - President, CEO & Chairman of the Board

Great. Thank you. And actually, thanks to Credit Suisse for giving us an opportunity to present to the audience here about Cytek. I'm Wenbin Jiang, CEO of the company; then Patrick, our CFO, over there.

Okay, perfect. Okay. As usual, the safe harbor statement, I don't expect you want me to read through. So I'm going to flip over. This is completely Cytek's leadership team, and many of them are already there for years. But I want to, in particular, introduce you Todd Garland, our Chief Commercial Officer joining us 6 months ago who has been leading Cytek's commercial activities, especially for our international sales. That's what he has been focusing on within the last 6 months. And Chris Williams just joined us a week ago from Thermo Fisher.

So to quickly go through a summary of where we are regarding to the company. As you can see, first years, we have a technology that has really been already validated by the number of instruments already placed actually through the end of Q3. We just announced our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot